Novavax, Inc. revised revenue guidance for the full year 2024. For the period, the company expects total revenue to be $400 million to $600 million compared to previous guidance of $800 million to $1,000 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.1 USD | -2.64% | +1.31% | +214.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+214.69% | 2.18B | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax, Inc. Revises Revenue Guidance for the Full Year 2024